Guidelines on the management of ascites in cirrhosis

What this platform has drawn from it — 3 claims

• The BSG/BASL ascites guideline states that refractory ascites should not be viewed as a contraindication to a non-selective beta blocker. Recommendation 10.1, section 10 'Non-selective beta-blockers (NSBB) and ascites' (quality of evidence: moderate; recommendation: strong)
  held in the ledger, not rendered on any page
• The BSG/BASL ascites guideline states that patients with refractory ascites taking a non-selective beta blocker should be monitored closely, and that dose reduction or discontinuation may be appropriate in those who develop hypotension or acute or progressive renal dysfunction. Recommendation 10.2, section 10 'Non-selective beta-blockers (NSBB) and ascites' (quality of evidence: moderate; recommendation: strong)
  held in the ledger, not rendered on any page
• The BSG/BASL ascites guideline limits its support for non-selective beta blockers in refractory ascites to their use when otherwise indicated, and unless alternative markers of circulatory failure such as hypotension or reduced glomerular filtration rate are present. Section 'Non-selective beta-blockers and ascites', concluding paragraph immediately preceding the recommendation box
  held in the ledger, not rendered on any page